SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 291.00 KRW | -81.79% |
| 2022 | 1596.18 KRW | -65.62% |
| 2021 | 4642.34 KRW | 979.79% |
| 2020 | 429.93 KRW | 124.09% |
| 2019 | 191.86 KRW | -8.61% |
| 2018 | 209.93 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -178.56 KRW | -428.84% |
| 2024 Q2 | -148.50 KRW | 16.83% |
| 2024 Q3 | -290.48 KRW | -95.29% |
| 2023 Q2 | -208.06 KRW | -11.97% |
| 2023 Q1 | -185.82 KRW | -151.43% |
| 2023 Q3 | 630.23 KRW | 402.91% |
| 2023 Q4 | 54.30 KRW | -91.38% |
| 2023 FY | - KRW | -81.79% |
| 2022 FY | - KRW | -65.62% |
| 2022 Q4 | 361.29 KRW | 33.32% |
| 2022 Q3 | 271.00 KRW | -54.91% |
| 2022 Q2 | 601.00 KRW | 65.56% |
| 2022 Q1 | 363.00 KRW | -85.17% |
| 2021 Q1 | 659.00 KRW | -59.17% |
| 2021 FY | - KRW | 979.79% |
| 2021 Q4 | 2447.67 KRW | 140.68% |
| 2021 Q3 | 1017.00 KRW | 46.75% |
| 2021 Q2 | 693.00 KRW | 5.16% |
| 2020 FY | - KRW | 124.09% |
| 2020 Q2 | -40.74 KRW | 50.61% |
| 2020 Q3 | 526.00 KRW | 1391.11% |
| 2020 Q4 | 1614.19 KRW | 206.88% |
| 2020 Q1 | -82.49 KRW | -104.49% |
| 2019 FY | - KRW | -8.61% |
| 2019 Q4 | 1839.16 KRW | 287.19% |
| 2019 Q3 | 475.00 KRW | -93.05% |
| 2019 Q2 | 6839.00 KRW | 269.03% |
| 2019 Q1 | -4046.00 KRW | -8.45% |
| 2018 Q4 | -3730.60 KRW | -194.66% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q3 | 3941.00 KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ORIENT BIO Inc. | 108.55 KRW | -168.079% |
| Green Cross Holdings Corporation | -1210.00 KRW | 124.05% |
| Green Cross Holdings Corporation | -2333.42 KRW | 112.471% |
| Pharmicell Co., Ltd. | 60.00 KRW | -385.0% |
| Green Cross Corporation | -2333.42 KRW | 112.471% |
| GeneOne Life Science, Inc. | -1000.23 KRW | 129.093% |
| Celltrion, Inc. | 3759.00 KRW | 92.259% |
| Samsung Biologics Co.,Ltd. | 12.05 Thousand KRW | 97.585% |
| SK Biopharmaceuticals Co., Ltd. | -419.89 KRW | 169.304% |
| Prestige BioPharma Limited | -547.81 KRW | 153.121% |